A summertime pause in immunoglobulin replacement therapy: a prospective real-world analysis.

To describe the effects of a summertime pause (SP) in immunoglobulin replacement therapy (IgRT). We conducted a prospective single-center observational study, including 44 patients undergoing intravenous IgRT between May and June 2019 in a French teaching hospital. IgRT was interrupted in 23 patients from June to October. Patients who underwent an SP were older, more likely to have secondary immunodeficiency (SID) and received lower doses of immunoglobulin and more antibiotics during winter. Most patients who did not undergo an SP had severe primary immunodeficiency. The SP did not increase the risk of infection, improved the quality of life and reduced treatment costs. SP in IgRT is a safe practice and should be considered for patients with mild SID.